MediPal Holdings Corp (MediPal) is a pharmaceutical company that carries out business essentially related to the sale and provision of services to the pharmaceutical, healthcare and beauty sectors. The company distributes prescription pharmaceuticals, medical equipment, clinical diagnostic reagents, specialty drugs, cosmetics, daily necessities, over-the-counter (OTC) pharmaceuticals, animal health products, food processing raw materials, and electronic materials. It serves medical institutions, hospitals, clinics, dispensing pharmacies, municipalities, drugstores, home improvement centers, convenience stores, supermarkets, veterinary clinics, animal hospitals, livestock and marine product producers, and processed food manufacturers across Japan.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

MediPal conducts specialized R&D initiatives across its business segments, focusing on prescription pharmaceuticals and food and chemical research. The company collaborates with JCR Pharmaceuticals on non-clinical and clinical testing of ultra-rare disease therapeutic candidates, such as JR-446 and JR-479, utilizing J-Brain Cargo technology. Its subsidiary, PALTAC Corporation, designs automated robotic pick-and-place arms integrating AI, while MP Gokyo Food & Chemical develops food-grade thickeners, biodegradable plastics, and electronic materials for semiconductors. The company is committed to developing therapeutic drugs for ultra-rare diseases, including fucosidosis and Mucopolysaccharidosis type IIIB, and aims to establish a system for R&D and marketing of rare disease medications globally. The R&D units of MediPal include the Tokyo Research Laboratory, Tokyo Open Lab, and Osaka Food & Chemical Research Center. In FY2026, the company spent JPY1,512 million on its R&D activities.